newsfilter
← Latest News
ACCESS Newswire·

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each year -- Phase 2b for DMT310 achieved statistically significant results for all primary endpoints - SAN